Want to learn how to develop an anti-AAV immunoassay using the automated Gyrolab® platform to pre-screen individuals for existing AAV immunity to maximize results of clinical/pre-clinical studies?
Listen to our online webinar:
Development of anti-AAV assay for detection of pre-existing AAV immunity
Zhe Liu, PhD
Staff Scientist,
Labcorp Early Development
AAV vectors are used in gene therapy products for treatment of genetic diseases. The high natural prevalence of AAV wild-type viruses has resulted in a high frequency of capsid-directed humoral immunity in human populations and many animal models, which may interfere with the therapeutic efficiency of a therapy if not identified and managed properly.
This case study describes the development of an anti-AAV immune assay for use in preclinical studies using cynomolgus monkeys, with the ability to screen for pre-existing AAV immunity and to identify low-responding individuals to maximize the likelihood of successful transduction.
- Importance of pre-screening for existing AAV immunity to maximize results of clinical/pre-clinical studies
- Development of anti-AAV immunoassay using an automated immunoassay platform
If you have problems viewing the webinar, please contact maritha.lundin@gyrosproteintech.com